VIDEO: Recent approvals in psoriatic arthritis

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

I would say this is a really exciting time to have psoriatic arthritis because we have so many different treatment options, and the ones that are most recent are the IL-23 inhibitors or risankizumab. This is not first in class, so we do have other IL-23 inhibitors, guselkumab, that we have already been approved for psoriatic arthritis, but now we have a new one. And then also in the family of the JAK inhibitors also not first in class, but we have ustekinumab that is available. As well as the TYK2 inhibitor, which is deucravacitinib, which is not recently approved but has been around for psoriasis and soon to be available for psoriatic arthritis. In terms of these new approvals, we're really excited about them because it gives us options for our patients. So the IL-23 inhibitors, probably we all know have a little bit more efficacy in skin and more comparable in joint disease to our TNF inhibitors. And then the JAK inhibitors such as the upadacitinib, and then the not quite yet approved but approved in psoriasis is the TYK2 inhibitor. So very exciting that we have options for our patients, but we still probably need to learn more about them in the real world practice to see how we can pick the right patients for the right drug.

Editor's note: Deucravacitinib is being evaluated for PsA.